Free Trial

Medpace (MEDP) Stock Price, News & Analysis

-6.83 (-1.72%)
(As of 05/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
106,632 shs
Average Volume
240,799 shs
Market Capitalization
$12.08 billion
P/E Ratio
Dividend Yield
Price Target

Medpace MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
13.6% Upside
$443.00 Price Target
Short Interest
3.72% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
1.08mentions of Medpace in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$59.63 M Sold Last Quarter
Proj. Earnings Growth
From $11.29 to $13.13 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.89 out of 5 stars

Medical Sector

25th out of 921 stocks

Commercial Physical Research Industry

1st out of 10 stocks

MEDP stock logo

About Medpace Stock (NASDAQ:MEDP)

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

MEDP Stock Price History

MEDP Stock News Headlines

Medpace (NASDAQ:MEDP) Trading Down 0.8%
Jefferies Reaffirms Their Buy Rating on Medpace Holdings (MEDP)
Q1 2024 Medpace Holdings Inc Earnings Call
Decoding 5 Analyst Evaluations For Medpace Hldgs
Medpace: Q1 Earnings Snapshot
See More Headlines
Receive MEDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Commercial physical research
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
$282.81 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.89 billion
Cash Flow
$9.89 per share
Book Value
$21.67 per share


Free Float
Market Cap
$12.08 billion
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

MEDP Stock Analysis - Frequently Asked Questions

Should I buy or sell Medpace stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MEDP shares.
View MEDP analyst ratings
or view top-rated stocks.

What is Medpace's stock price target for 2024?

5 Wall Street analysts have issued 1-year target prices for Medpace's shares. Their MEDP share price targets range from $395.00 to $464.00. On average, they anticipate the company's share price to reach $443.00 in the next year. This suggests a possible upside of 13.6% from the stock's current price.
View analysts price targets for MEDP
or view top-rated stocks among Wall Street analysts.

How have MEDP shares performed in 2024?

Medpace's stock was trading at $306.53 at the beginning of 2024. Since then, MEDP stock has increased by 27.2% and is now trading at $389.82.
View the best growth stocks for 2024 here

When is Medpace's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, July 22nd 2024.
View our MEDP earnings forecast

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) issued its quarterly earnings data on Monday, April, 22nd. The company reported $3.20 earnings per share for the quarter, topping the consensus estimate of $2.45 by $0.75. The business had revenue of $511 million for the quarter, compared to analysts' expectations of $512.39 million. Medpace had a net margin of 15.92% and a trailing twelve-month return on equity of 59.74%. The firm's revenue for the quarter was up 17.7% on a year-over-year basis. During the same quarter last year, the firm earned $2.27 EPS.

What guidance has Medpace issued on next quarter's earnings?

Medpace issued an update on its FY 2024 earnings guidance on Monday, April, 22nd. The company provided EPS guidance of 10.790-11.470 for the period, compared to the consensus estimate of 10.610. The company issued revenue guidance of $2.2 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion.

What is August Troendle's approval rating as Medpace's CEO?

268 employees have rated Medpace Chief Executive Officer August Troendle on August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

When did Medpace IPO?

Medpace (MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Who are Medpace's major shareholders?

Medpace's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.08%), Wasatch Advisors LP (3.15%), Riverbridge Partners LLC (1.96%), TD Asset Management Inc (1.85%), Epoch Investment Partners Inc. (1.31%) and Bessemer Group Inc. (1.27%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Robert O Kraft, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc.
View institutional ownership trends

How do I buy shares of Medpace?

Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MEDP) was last updated on 5/23/2024 by Staff

From Our Partners